So Jace, what Glynn is saying is that the company won't release any information of any substance unless happens to be a cut and paste from a document received from a 'client'? Makes one wonder what the heck the company is doing the rest of the time considering haven't seen any new patents for ages, no new clients, and for the existing 'clients' the usual commentary that the board is waitng on their moves. Really is getting tiresome. BG - no updates, both Coty and GSK feature on the website but might as well cut and paste info from the 2013 report into this one since no updates of worth, and the PG deal of the century, well still no money or guidance. Hell even in my field, clients will provide information as to the frequency of use of our products by which to gauge licensing estimates!
Really is time to pile on some pressure in terms of the 2017 'performance' bonuses - really nothing to note so far indicating performance. As many posters have echoed, cash flow is the next catalyst (or at worst, justification) required.
Guess we can wait for the report followed by the inhouse speculation as to which products from Olay to toothbrushes may or may not appear before the Olympics. Closely followed by a rehash in advance of Christmas, next the Chinese New Year, and a repeat of all things optimistic in time for next Easter Monday (a date well known for it's curative and resurrective properties that Obj could stand a little assistance with).
OBJ Price at posting:
7.8¢ Sentiment: Hold Disclosure: Held
(20min delay)